Background: recently, the Food and Drug Administration issued a recall for the subcutaneous implantable cardioverterdefibrillator (S-ICD) because of the possibility of lead ruptures and accelerated battery depletion.

Objective: the aim of this study was to evaluate device-related complications over time in a large real-world multicenter S-ICD cohort.

Methods: patients implanted with an S-ICD from January 2015 to June 2020 were enrolled from a 19-institution European registry (Experience from the Long-term Italian S-ICD registry [ELISIR]; ClinicalTrials.gov identifier NCT0473876). Device-related complication rates over follow-up were collected. Last follow-up of patients was performed after the Boston Scientific recall issue.

Results: a total of 1.254 patients (median age 52.0 [interquartile range 41.0-62.2] years; 973 (77.6%) men; 387 (30.9%) ischemic) was enrolled. Over a follow-up of 23.2 (12.8-37.8) months, complications were observed in 117 patients (9.3%) for a total of 127 device-related complications (23.6% managed conservatively and 76.4% required reintervention). Twentyseven patients (2.2%) had unanticipated
generator replacement after 3.6 (3.3-3.9) years, while 4 (0.3%) had lead rupture. Body mass index (hazard ratio [HR] 1.063 [95% confidence interval 1.028-1.100]; P<.001), chronic kidney disease (HR 1.960 [1.191-3.225]; P=.008), and oral anticoagulation (HR 1.437 [1.010-2.045]; P=.043) were associated with an increase in overall complications, whereas older age (HR 0.980 [0.967-0.994]; P=.007) and procedure performed in high-volume centers (HR 0.463 [0.300-0.715]; P=.001) were protective factors. Conclusion: the overall complication rate over 23.2 months of follow-up in a multicenter S-ICD cohort was 9.3%. Early unanticipated device battery depletions occurred in 2.2% of patients, while lead fracture was observed in 0.3%, which is in line with the expected rates reported by Boston Scientific.